Trial · NCT02431702
Adverse events210
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 210
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Part 1-Run-in: Oral Antipsychotics (OAP) | 5 | 273 | |
| other | Nausea | Gastrointestinal disorders | Part 2-Paliperidone Palmitate (PP) | 4 | 78 | |
| other | Nausea | Gastrointestinal disorders | Part 2-OAP | 11 | 157 | |
| other | Nausea | Gastrointestinal disorders | Part 3-PP to PP (Extended Disease Progression [EDP] and Disease Modification) | 2 | 49 | |
| other | Nausea | Gastrointestinal disorders | Part 3- OAP to PP (or Delayed-Start PP) (Disease Modification) | 2 | 57 | |
| other | Nausea | Gastrointestinal disorders | Part 3-OAP to OAP (EDP and Disease Modification) | 5 | 63 | |
| other | Fatigue | General disorders | Part 1-Run-in: Oral Antipsychotics (OAP) | 10 | 273 | |
| other | Fatigue | General disorders | Part 2-Paliperidone Palmitate (PP) | 4 | 78 | |
| other | Fatigue | General disorders | Part 2-OAP | 1 | 157 | |
| other | Fatigue | General disorders | Part 3-PP to PP (Extended Disease Progression [EDP] and Disease Modification) | 0 | 49 | |
| other | Fatigue | General disorders | Part 3- OAP to PP (or Delayed-Start PP) (Disease Modification) | 5 | 57 | |
| other | Fatigue | General disorders | Part 3-OAP to OAP (EDP and Disease Modification) | 1 | 63 | |
| other | Injection Site Pain | General disorders | Part 1-Run-in: Oral Antipsychotics (OAP) | 4 | 273 | |
| other | Injection Site Pain | General disorders | Part 2-Paliperidone Palmitate (PP) | 6 | 78 | |
| other | Injection Site Pain | General disorders | Part 2-OAP | 2 | 157 | |
| other | Injection Site Pain | General disorders | Part 3-PP to PP (Extended Disease Progression [EDP] and Disease Modification) | 0 | 49 | |
| other | Injection Site Pain | General disorders | Part 3- OAP to PP (or Delayed-Start PP) (Disease Modification) | 0 | 57 | |
| other | Injection Site Pain | General disorders | Part 3-OAP to OAP (EDP and Disease Modification) | 0 | 63 | |
| other | Nasopharyngitis | Infections and infestations | Part 1-Run-in: Oral Antipsychotics (OAP) | 1 | 273 | |
| other | Nasopharyngitis | Infections and infestations | Part 2-Paliperidone Palmitate (PP) | 5 | 78 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02431702/events